Celsion Reports Interim Data for Liver Cancer Trial

Favorable interim results were seen in Celsion’s second Phase I liver cancer study of ThermoDox combined with radio-frequency ablation (RFA) in treating patients with primary and metastatic liver cancer.

Data showed the local return of cancer was seen in two of 44 tumors treated with RFA plus the drug, resulting in a 4.5 percent local recurrence rate. Five of the 10 evaluated patients demonstrated a complete response along with a single partial response.

ThermoDox is a heat-sensitive form of doxorubicin, a drug frequently used in treating various cancers, according to the company.